AHR and triple-negative breast carcinoma: In triple-negative breast cancer – characterized by lack of expression of ER, progesterone receptor (PR), and lack of human epidermal growth factor receptor 2 (HER2) overexpression – TDO is particularly elevated and drives AhR activity to promote migration, anoikis resistance, and tumor metastasis (25, 27).